KimBS, HowellMD, SunK, et al.Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol, 2020; 145(2):572–582. doi:.
2.
BissonnetteR, PappKA, PoulinY, et al.Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol, 2016; 175(5):902–911. doi:.
3.
NakagawaH, NemotoO, IgarashiA, et al.Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol, 2020; 82(4):823–831. doi:.
4.
Julián-GónzalezRE, Orozco-CovarrubiasL, Durán-McKinsterC, et al.Less common clinical manifestations of atopic dermatitis: prevalence by age. Pediatr Dermatol, 2012; 29(5):580–583. doi:.
5.
HenggeUR, RuzickaT, SchwartzRA, et al.Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol, 2006; 54(1):1–15. doi:.
